Literature DB >> 26212610

Generation of potent dendritic cells with improved migration ability through p-cofilin and sarco/endoplasmic reticulum Ca(2+) transport ATPase 2 regulation.

Nu-Ri Choi1, Hyun-Ju Lee1, Sung-Hoon Jung2, Cheol Yi Hong1, Manh-Cuong Vo1, My-Dung Hoang1, Hyeoung-Joon Kim3, Je-Jung Lee4.   

Abstract

BACKGROUND AIMS: It is important to improve the migratory ability of dendritic cells (DCs) and to increase DC potency for successful DC-based cancer immunotherapy. The intracellular Ca(2+) signaling pathway has an important role on the regulation of DC migration. Our preliminary studies revealed that sarco/endoplasmic reticulum Ca(2+) transport ATPase 2 (SERCA2) expression was inversely related to DC migratory capacity, and the expression level of p-cofilin and SERCA2 on mature DCs showed a counter-trend.
METHODS: We selected the appropriate six maturation cocktails on the basis of the expression levels of SERCA2 and p-cofilin and investigated the functional characteristics and migratory capacity of mature DCs. Among the these six maturation cocktails, DCIFN-γ/IL-1β/Poly-I:C showed potent type 1 immune response with interleukin (IL)-12p70 production and strong Th1-polarization, and this DC elicited strong antigen-specific cytotoxic T-lymphocyte responses.
RESULTS: Interestingly, DCIFN-γ/IL-1β/Poly-I:C showed lower expression of SERCA2 and higher expression of p-cofilin compared with those matured with the use of other cocktails. In vitro migration assay showed that DCs matured with the use of this maturation cocktail had significantly increased migratory ability compared with αDC1s and other DCs.
CONCLUSIONS: Interferon-γ, IL-1β and Poly-I:C maturation cocktail may be used in the field of cancer immunotherapy to generate potent immune-stimulatory DCs with improved type 1 immune response and migration capacity.
Copyright © 2015 International Society for Cellular Therapy. Published by Elsevier Inc. All rights reserved.

Entities:  

Keywords:  SERCA2; chemotaxis; dendritic cell; migration

Mesh:

Substances:

Year:  2015        PMID: 26212610     DOI: 10.1016/j.jcyt.2015.06.002

Source DB:  PubMed          Journal:  Cytotherapy        ISSN: 1465-3249            Impact factor:   5.414


  7 in total

1.  Potent anti-myeloma efficacy of dendritic cell therapy in combination with pomalidomide and programmed death-ligand 1 blockade in a preclinical model of multiple myeloma.

Authors:  Tan-Huy Chu; Manh-Cuong Vo; Hye-Seong Park; Thangaraj Jaya Lakshmi; Sung-Hoon Jung; Hyeoung-Joon Kim; Je-Jung Lee
Journal:  Cancer Immunol Immunother       Date:  2020-07-04       Impact factor: 6.968

2.  Sarcoplasmic reticulum Ca(2+) ATPase 2 (SERCA2) reduces the migratory capacity of CCL21-treated monocyte-derived dendritic cells.

Authors:  Cheol Yi Hong; Hyun-Ju Lee; Nu-Ri Choi; Sung-Hoon Jung; Manh-Cuong Vo; My Dung Hoang; Hyeoung-Joon Kim; Je-Jung Lee
Journal:  Exp Mol Med       Date:  2016-08-19       Impact factor: 8.718

3.  Combination therapy with dendritic cells and lenalidomide is an effective approach to enhance antitumor immunity in a mouse colon cancer model.

Authors:  Manh-Cuong Vo; Thanh-Nhan Nguyen-Pham; Hyun-Ju Lee; Thangaraj Jaya Lakshmi; Seoyun Yang; Sung-Hoon Jung; Hyeoung-Joon Kim; Je-Jung Lee
Journal:  Oncotarget       Date:  2017-04-18

4.  Synergistic Antimyeloma Activity of Dendritic Cells and Pomalidomide in a Murine Myeloma Model.

Authors:  Manh-Cuong Vo; Seoyun Yang; Sung-Hoon Jung; Tan-Huy Chu; Hyun-Ju Lee; Thangaraj Jaya Lakshmi; Hye-Seong Park; Hyeoung-Joon Kim; Je-Jung Lee
Journal:  Front Immunol       Date:  2018-08-03       Impact factor: 7.561

Review 5.  Cellular immunotherapy in multiple myeloma.

Authors:  Manh-Cuong Vo; Thangaraj Jaya Lakshmi; Sung-Hoon Jung; Duck Cho; Hye-Seong Park; Tan-Huy Chu; Hyun-Ju Lee; Hyeoung-Joon Kim; Sang-Ki Kim; Je-Jung Lee
Journal:  Korean J Intern Med       Date:  2019-02-15       Impact factor: 2.884

6.  Chaetocin enhances dendritic cell function via the induction of heat shock protein and cancer testis antigens in myeloma cells.

Authors:  Manh-Cuong Vo; Thanh-Nhan Nguyen-Pham; Hyun-Ju Lee; Sung-Hoon Jung; Nu-Ri Choi; My-Dung Hoang; Hyeoung-Joon Kim; Je-Jung Lee
Journal:  Oncotarget       Date:  2017-07-11

7.  Lenalidomide and Programmed Death-1 Blockade Synergistically Enhances the Effects of Dendritic Cell Vaccination in a Model of Murine Myeloma.

Authors:  Manh-Cuong Vo; Sung-Hoon Jung; Tan-Huy Chu; Hyun-Ju Lee; Thangaraj Jaya Lakshmi; Hye-Seong Park; Hyeoung-Joon Kim; Joon Haeng Rhee; Je-Jung Lee
Journal:  Front Immunol       Date:  2018-06-18       Impact factor: 7.561

  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.